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Clinical implications of mutation analysis in primary hyperox-
aluria type 1.
Background. Primary hyperoxaluria type 1 (PH1) is an in-
born error of glyoxylate metabolism with an extensive clinical
and genetic heterogeneity. Although over 50 disease-causing
mutations have been identified, the relationship between geno-
type and clinical outcome remains unclear. The aim of this study
was to determine this association in order to find clues for im-
provement of patient care.
Methods. AGXT mutation analysis and assessment of bio-
chemical characteristics and clinical outcome were performed
on patients from a Dutch PH1 cohort.
Results. Thirty-three of a cohort of 57 PH1 patients, identified
in The Netherlands over a period of 30 years, were analyzed.
Ten different mutations were found. The most common muta-
tions were the Gly170Arg, Phe152Ile, and the 33insC mutations,
with an allele frequency of 43%, 19%, and 15%, respectively.
Homozygous Gly170Arg and Phe152Ile mutations were asso-
ciated with pyridoxine responsiveness and a preserved renal
function over time when treatment was timely initiated. All pa-
tients homozygous for the 33insC mutation had end-stage renal
disease (ESRD) before the first year of age. In two unrelated
patients, a new Val336Asp mutation was found coupled with the
Gly170Arg mutation on the minor allele. We also found 3 pa-
tients homozygous for a novel Gly82Arg mutation with adverse
outcome in 2 of them.
Conclusion. Early detection of Gly170Arg and Phe152Ile
mutations in PH1 has important clinical implications because
of their association with pyridoxine responsiveness and clini-
cal outcome. The association of a homozygous 33insC mutation
with severe infantile ESRD, resulting in early deaths in 2 out
of 3 cases, warrants a choice for prenatal diagnostics in affected
families.
Primary hyperoxaluria type 1 (PH 1) is a rare
autosomal-recessive inborn error of glyoxylate meta-
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bolism caused by a functional deficiency of the perox-
isomal liver-specific enzyme alanine:glyoxylate amino-
transferase (AGT). This enzyme deficiency leads to an
overproduction of oxalate and, in most cases, of glyco-
late. The accumulation of oxalate causes insoluble cal-
cium oxalate depositions in renal tissue and, in case
of renal insufficiency, systemic tissue damage caused by
oxalate storage. Clinically, symptoms can vary from infre-
quently occurring renal stones to early onset nephrocal-
cinosis and end-stage renal disease (ESRD) with severe
systemic disease.
PH1 is caused by mutations in the AGXT gene en-
coding AGT. The AGXT gene is located at 2q37.3 and
consists of 11 exons, ranging from 65 bp to 407 bp [1]. To
date, 7 polymorphisms and more than 50 different muta-
tions have been found in the AGXT gene. Two different
haplotypes have been identified based on the presence
or absence of three specific polymorphic variants: the
major (frequency 80%) and the minor haplotype (fre-
quency 20%). The latter is defined by a 74 bp duplica-
tion within the first intron, and by 32C>T and 1020A>G
point mutations, which lead to Pro11Leu and Ile340Met
amino acid substitutions. In healthy individuals who are
homozygous for the minor haplotype (frequency of 4% in
the Caucasian population), 5% of AGT is mistargeted to
mitochondria instead of to peroxisomes. In combination
with a Gly170Arg substitution, however, this minor hap-
lotype leads to mistargetting to the mitochondria of 90%
of AGT. This not only causes a significant reduction of its
activity in vivo, but also has consequences for its function-
ing in glyoxylate metabolism. Several other mutations
causing amino acid substitutions have shown to be associ-
ated with specific AGT phenotypes: the Gly82Glu substi-
tution abolishes AGT catalytic activity, and the Gly41Arg
substitution and Ile244Thr substitution both lead to pro-
tein destabilization and aggregation into inclusion bodies
[2].
Although several studies have established a rela-
tion between genotype and in vitro AGT function-
ing, the association between genotype and biochemical
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Table 1. AGXT-specific primers used for mutation analysis of PH1 patients
Exon 5′ Primer 3′ Primer
1 and 2 [-21M13]- AAG CAC AGA TAA GCC TCA GG [M13-Rev]-GAT GGA TCC AGG GCC ATC CC
3 and 4 [-21M13]-GAC ACT CAC GGC CCA CTC TG [M13-Rev]-GAG CTG TGC TCC AGT CCA CC
5 and 6 [-21M13]-TCA CCT GCT GCC CTC CAT TC [M13-Rev]-TGC ACA GAG GTG AGG GTC TG
7 and 8 [-21M13]-ACT GAG AGG CTG GTG CTC AG [M13-Rev]-AGT GCG CCT GTC TCC TCC TG
9 and 10 [-21M13]-CAC CCA TGT CAC TGC CCA CC [M13-Rev]-CAC CTG GTG CAC AGT CCT GC
11 [-21M13]-AGG CGG GAG GCT GAC GTC AG [M13-Rev]-CTC CTC TCA CTC TTT CAC AG
[-21M13]: 5′-TGTAAAACGACGGCCAGT-3′.
[M13-Rev]: 5′-CAGGAAACAGCTATGACC-3′.
characteristics in vivo is less evident. One of the most im-
portant unanswered questions is the relationship between
clinical outcome and genotype. In order to investigate this
relationship, we reviewed the biochemical characteristics,
as well as the clinical outcome, in 33 patients of a Dutch
cohort of all known PH1 patients over a period of 30 years
in whom we were able to obtain DNA.
METHODS
Patients
Recently, we described a cohort of 57 patients with PH1
diagnosed between 1970 and 2000 in The Netherlands [3].
From this cohort, we approached all living patients and/or
their parents to participate in this study. Furthermore,
we isolated DNA from liver biopsy tissue of 2 deceased
PH1 patients. Patients who were diagnosed after the year
2000 were also approached, and, after informed consent
was received, information on their clinical status was
obtained.
Diagnosis of PH1 was made if either deficient AGT
activity in the liver samples or the combination of hyper-
oxaluria and hyperglycolic aciduria (24-hour urine ex-
cretion exceeding 0.5 mmol/L oxalate or 0.054 mmol/L
oxalate/mmol/L creatinine and 0.14 mmol/L glyco-
late/mmol/L creatinine, respectively) was demonstrated.
Renal function was estimated by the Cockroft formula in
adults and the Schwartz formula in children using plasma
creatinine values [4, 5]. For patients in whom urinary ox-
alate could not be measured because of anuria, highly
elevated plasma oxalate levels of more than 20 times the
upper limit of the reference range (<5 lmol/L) were con-
sidered to be caused by PH1 and not by renal insufficiency
itself [6]. Patients in whom only hyperoxaluria was estab-
lished were considered to have PH1 if measurements in
liver biopsies demonstrated deficient AGT activities in
other family members. When these firm grounds were not
present, we decided to include only patients with the fol-
lowing highly suspicious circumstantial evidence for PH1:
(1) significant response to pyridoxine therapy; and (2) se-
vere systemic oxalosis. Renal insufficiency was defined as
a creatinine clearance of <60 mL/min/1.73 m2. ESRD was
defined as a creatinine-clearance of <10 mL/min/1.73 m2
body surface area (BSA). Mutations in the AGXT gene
were investigated in relation to pyridoxine responsive-
ness and outcome. Pyridoxine responsiveness was defined
by a decline of urinary or plasma oxalate levels of >30%
in at least 2 urine samples upon pyridoxine therapy [7].
We calculated the prescribed dosages of pyridoxine per
kg body weight in patients in which response of pyridox-
ine on oxalate excretion was measured. AGT enzyme ac-
tivities were determined in liver samples as described, and
are expressed as percentages of the mean AGT activity
determined in control liver samples [8].
Mutation analysis
Genomic DNA was extracted from lymphocytes using
the Wizard Genomic DNA purification kit according to
the instructions of the supplier (Promega, Madison, WI,
USA). Six sets of AGXT-specific primers with −21M13
or M13rev extensions were used for the amplification of
the entire AGXT coding region encoded by exon 1 to 11
(Table 1). Each polymerase chain reaction (PCR) con-
tained 0.4 lmol/L of each primer (synthesized by Phar-
macia, Uppsala, Sweden), 10 mmol/L Tris/HCl pH 8.4, 50
mmol/L KCl, 1.5 or 2 mmol/L MgCL2, 0.01% w/v bovine
serum albumin (BSA), 0.2 mmol/L dNTP (Pharmacia),
and 0.5 lL Taq DNA polymerase (Promega). Two differ-
ent PCR programs were used to amplify the exons. For
exons 1, 2, 3, 4, and 11, the amplification started with 2
minutes of denaturation at 96◦C, followed by 5 cycles of
30 seconds at 96◦C, 30 seconds at 55◦C, and 1 minute at
72◦C, and 25 cycles of 30 seconds at 94◦C, 30 seconds at
55◦C, and 1 minute at 72◦C, with a final extension step
of 7 minutes at 72◦C. For exons 5 to 10, the amplification
started with 2 minutes of denaturation at 96◦C, followed
by 5 cycles of 30 seconds at 96◦C, 30 seconds at 55◦C, and
2 minutes at 72◦C, and 25 cycles of 30 seconds at 94◦C,
30 seconds at 55◦C, and 2 minutes at 72◦C, with a final
extension step of 7 minutes at 72◦C. The PCR fragments
were analyzed by direct sequencing using the Big Dye
Terminator Cycle Sequencing Kit or the Big Dye Primer
Cycle sequencing kit (Applied Biosystems, Foster City,
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Table 2. Patient characteristics
Total number of patients 33
Median age at time of investigation years 27 (3–63)
Male/female 15/18
Median age at time of diagnosis years 6.6 (0–50)
Urolithiasis 19
Nephrocalcinosis 17
Pyridoxine sensitivity 15
Renal insufficiency at the time of diagnosis 15
ESRD at the time of diagnosis 14
ESRD/renal insufficiency at follow-up 21
Infantile onset 8
Kidney transplantation 12 in 10 patients
Combined liver/kidney transplantation 6
Deceased 2
ESRD, end-stage renal disease.
CA, USA) on an ABI 3100 automated DNA se-
quencer according to the manufacturer’s protocol (Ap-
plied Biosystems). Mutation analysis was performed with
DNA of the probands and, when available, with DNA
of the parents in order to establish the zygosity of the
probands.
The study design was approved by the Medical Ethics
Committee of the Academic Medical Center, and in-
formed consent was obtained from the participants or
their parents.
RESULTS
Clinical data
We identified 57 PH1 patients in The Netherlands over
a period of 30 years [3]. For the present study we obtained
material for DNA analysis of 33 of these 57 patients, 2 of
whom had died at the time of investigation. These 33
patients were the offspring of 26 families. Patient charac-
teristics are given in Table 2; mutational data, biochem-
ical phenotype, and clinical outcome of all patients are
presented in Table 3. Consanguinity was reported in one
family (family 5, Table 3). The ethnic origin varied: Dutch
(23), Turkish (2), Surinam (3), Albanian (4), and mixed
Dutch-Turkish (1). The median age at diagnosis was 6.6
(range 0 to 57) years. Twenty (59%) patients were diag-
nosed under the age of 18, 6 (18%) in the first year of life.
At the time of diagnosis, 15 patients (44%) had renal in-
sufficiency, 14 of whom had already developed ESRD. No
differences in time of follow-up were found between the
patients with a stable renal function and those who devel-
oped renal insufficiency [median (range) follow-up: 13.1
(0 to 47) and 7.7 (0 to 46) years, respectively]. AGT activ-
ity was measured in the liver samples of 21 patients. The
median AGT activity was 9.5% of control values (range
1% to 47%). Pyridoxine therapy was initially started in
16 patients. In 13 of these 16 patients, pyridoxine therapy
induced a significant decrease of the oxalate excretion. In
two additional patients, pyridoxine was successfully pre-
scribed after isolated kidney transplantation (patients 8
and 18, Table 3).
Kidney transplantation was primary performed in 9
and combined liver-kidney transplantation in 6 patients.
Two patients received a second isolated renal graft, 8
and 6 years, respectively, after their first transplantation,
and in one patient combined liver kidney transplanta-
tion was performed 7 years after the first isolated kidney
transplantation. In one patient, isolated kidney trans-
plantation was performed after combined liver kidney
transplantation. Renal graft functions were preserved in
5 patients with isolated kidney transplantation for 2, 3, 3,
9, and 14.5 years, respectively (Table 3). Of all 6 patients
with combined liver kidney transplantation, one patient
died as a consequence of liver failure, and one patient
developed severe cirrhosis. One patient showed a dete-
rioration of the renal function; the other 3 patients had
a preserved renal and liver function after a follow-up of
1, 4, and 7 years, respectively.
Gene mutations
Eight different mutations were found in 26 unrelated
probands (Table 4). We found the Gly170Arg mutation in
20 patients (60.6%), 15 of whom were unrelated. The al-
lele frequency was 44%. Seven patients were compound
heterozygous, and 8 were homozygous for this mutation.
The minor allele, consisting of the Pro11Leu polymor-
phism and the 74-bp insertion in the first intron, always
co-segregated with this mutation.
Eight patients, 7 of whom were unrelated, carried the
Phe152Ile mutation (allele frequency 19%).
The 33insC mutation was found in 5 patients (allele fre-
quency 15%). In 2 patients (patients 15 and 22, Table 3),
a novel mutation was identified on the Gly170Arg allele:
an amino acid change Val336Asp (1007T>A mutation).
In 4 cases (patients 12, 13, 14, 23, Table 3), only 1 het-
erozygous mutation was found. Of 6 probands, another 7
siblings were diagnosed by screening (Table 3). Sequenc-
ing revealed the same mutations in each affected family.
In 3 patients of 2 unrelated families, we found homozy-
gosity for a previously unrecognized 121G>A (244G>A)
mutation, resulting in a Gly82Arg substitution.
Associations between genotype and phenotype
The Gly170Arg and Val336Asp mutations. Of the 12
patients who were homozygous for the G170Arg mu-
tation (patients 1 to 11 and 15, Table 3), 5 had devel-
oped ESRD at time of diagnosis. Pyridoxine respon-
siveness was observed in 6 of all 7 patients in whom
pyridoxine responsiveness was measured. In 1 additional
patient with ESRD at time of diagnosis, pyridoxine re-
sponsiveness was established after kidney transplanta-
tion. The only patient without response upon pyridoxine
administration developed renal insufficiency. Remark-
ably, this patient was also homozygous for a second, pre-
viously unrecognized mutation: the Val336Asp mutation.
This novel mutation, in association with the Gly170Arg
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Table 3. Mutations and clinical characteristics of all patients
Age at Renal function/
onset/ Age at Renal outcome at
Patient diagnosis follow-up function at at follow-up Pyr D
(family) Mutation (allele) years years diagnosis age Tx age PyrR mg/kg AGT%
1 (1) Gly170Arg (m)/Gly170Arg (m) 5/5 13 Normal Preserved + 2.5 47.4
2 (2) Gly170Arg (m)/Gly170Arg (m) 42/42 53 ESRD Tx preserveda K (44) ND ND ND
3 (3) Gly170Arg (m)/Gly170Arg (m) 35/35 49 Normal Preserved + 14.2 46.9
4 (3) Gly170Arg (m)/Gly170Arg (m) 6/6 55 Normal ESRD (51)/Tx K (52) + 11.4 14.9
preserveda
5 (3) Gly170Arg (m)/Gly170Arg (m) 48/48 53 ESRD ESRD ND ND ND
6 (4) Gly170Arg (m)/Gly170Arg (m) 10/16 36 ESRD Tx preserveda K (22) ND ND ND
7 (5) Gly170Arg (m)/Gly170Arg (m) 7/7 34 Normal Preserved + 7.1 34.0
8 (5) Gly170Arg (m)/Gly170Arg (m) 25/25 38 Normal ESRD (34)/Tx K (36) +b 14.2 ND
preserveda
9 (6) Gly170Arg (m)/Gly170Arg (m) 0.5/3.5 17.8 ESRD Tx decreased K(9)K(17) ND ND 30.0
functiona
10 (7) Gly170Arg (m)/Gly170Arg (m) 50/50 58 ESRD Tx decreased K(50)K(56) ND ND 37.1
functiona
11 (7) Gly170Arg(m)/Gly170Arg (m) 57/57 61 Normal Preserved + 6.6 ND
12 (8) Gly170Arg (m)/Xo (M) 0.4/0.4 11 ESRD ESRD (4)/Tx LK(4)K(6) ND ND ND
preserveda
13 (8) Gly170Arg (m)/Xo (M) 0.3/0.3 15 Normal Preserved + 13.6 5.2
14 (9) Gly170Arg (m)/Xo (m) 0.5/0.5 3 Normal Preserved + 30 6.2
15 (10) Gly170Arg-Val336Asp (m)/ 5/5 8 Decreased Decreasing – 4.0 4.5
Gly170Arg-Val336Asp (m)
16 (11) Gly170Arg (m)/Leu153Val (M) 27/27 39 ESRD ESRD/Tx- K(31)LK(38) ND ND 16.4
preserveda
17 (12) Phe152Ile (m)/Phe152Ile (m) 2/2 31 Normal Preserved + 12.5 12.9
18 (13) Phe152Ile (m)/Phe152Ile (m) 25/30 59 ESRD Tx decreasing K(31) +b 14.3 ND
slowlya
19 (14) Phe152Ile (m)/Phe152Ile (m) 31/31 37 ESRD ESRD ND ND ND
20 (14) Phe152Ile (m)/Phe152Ile (m) 22/22 26 Normal Preserved + 2.9 10.0
21 (15) Phe152Ile (m)/Gly170Arg (m) 1/1 10 Normal Preserved + 7.5 10.0
22 (16) Phe152Ile (m)/Gly170Arg- 4/4 20 Normal Decreased + 6.0 10.2
Val336Asp (m)
23 (17) Phe152Ile/Xo (mm) 40/40 44 ESRD ESRD ND ND 16.6
24 (18) Phe152Ile (m)/33insC (M) 2/2 27 Normal Preserved + 6.0 5.9
25 (19) 33insC (M)/33insC (M) 0.1/0.1 8 ESRD Tx preserveda LK (1.7) ND ND 5.2
26 (20) 33insC (M)/33insC (M) 0.5/0.5 0.6 ESRD Died ND ND 1.1
27 (21) 33insC (M)/33insC (M) 0.6/0.6 1.3 ESRD Died (liver failure) LK (1.3) ND ND 5.0
28 (22) 33insC (M)/Gly170Arg (m) 4/14 23 ESRD Tx preserveda/liver LK (16.5) ND ND ND
failure
29 (23) 33insC (M)/Gly170Arg (m) 6/6 29 Normal Preserved + 8.0 16.3
30 (24) Gly82Arg (m)/Gly82Arg (m) 0.6/0.6 16 Normal Preserved ND ND ND
31 (25) Gly82Arg (m)/Gly82Arg (m) 6/6 19 Normal ESRD (18)/Tx LK(19) – 5.7 3.6
decreasinga
32 (25) Gly82Arg (m)/Gly82Arg (m) 7/7 21 Normal Decreased – 20.0 ND
33 (26) C173X (M)/IVS1-1G>A (M) 0.2/0.2 14 ESRD Tx preserveda K(11) ND ND 4.1
Abbreviations are: m, minor allele; M, major allele; PyrR, pyridoxine responsiveness ≥30% reduction of U-oxalate under pyridoxine; Pyr D, pyridoxine dosage in
mg/kg: minimal dosage with >30% response of U-oxalate or maximum prescribed dosage in case of no response on oxalate excretion; AGT%, percentage AGT-activity
in vitro related to AGT-activity in vitro of control tissue; K, kidney transplantation; LK, combined liver-kidney transplantation; ESRD, end-stage renal disease; ND,
not determined; Tx, transplantation.
aRenal graft function; bdetermined after transplantation.
allele, was also identified heterozygous in another pa-
tient who was initially pyridoxine responsive, but showed
nevertheless a decline of renal function at follow-up. All
but 2 homozygous Gly170Arg patients with a normal re-
nal function at time of diagnosis (and without the addi-
tional Val336Asp mutation) preserved their renal func-
tion over time. The 2 patients that developed ESRD over
time were unfortunately both lost to follow-up in the pe-
riod between diagnosis and onset of dialysis; both patients
had not been treated with pyridoxine, potassium citrate,
and/or high fluid intake. After kidney transplantation,
both patients were responsive to pyridoxine therapy and
preserved their renal function to date with a graft sur-
vival of 3 and 14.5 years, respectively (patients 4 and 8,
Table 3).
Four out of 6 homozygous Gly170Arg patients who
received a renal graft were able to preserve their renal
functions after a mean follow-up of 8 (range 3 to 14.5)
years.
The Phe152Ile mutation. In 2 out of all 4 homozygous
Phe152Ile patients (patients 17 and 20, Table 3), pyri-
doxine therapy was used successfully in reducing urinary
oxalate excretion. Both patients preserved their renal
function over time, with a follow-up of 4 and 29 years,
respectively. The 2 other patients had ESRD at time of
diagnosis. In one of them (patient 18, Table 3), pyridoxine
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Table 4. Mutations in the AGXT gene in Dutch PH1 patients
Mutationa Exonb Allelec Coding effect
IVS1-1G>A Intron 1 Major Splicing defect
33insC (156insC) 1 Major Frame shift
244G>C (336G>C) 2 Minor Gly82Arg
454T>A (576T>A) 4 Minor Phe152Ile
457T>G (579T>G) 4 Major Leu153Val
508G>A (630G>A) 4 Minor Gly170Arg
519C>A (641C>A) 5 Major Cys173STOP
1007T>A 6 Minor Val336Aspd
aNucleotide numbering starts from the first AUG (position 123) according to
cDNA sequence of GenBank Accession number NM 000030. Between brackets
the notation according to the previously introduced numbering system which
starts at the first nucleotide of this cDNA sequence.
bExon-intron numbering according to Purdue et al [18].
cMinor allele is defined by the presence of a 74-bp duplication in intron 1 and
the 32C>T (Pro11Leu) and 1020A>G (Ile340Met) polymorphic variants, which
are absent on the major allele.
dThe Val336Asp mutation cosegregates with the Gly170Arg mutation on the
minor allele.
therapy was initiated at the onset of hemodialysis treat-
ment, resulting in a significant fall in serum oxalate, which
continued to decrease after isolated kidney transplanta-
tion. However, renal function slowly decreased through-
out the follow-up period due to a chronic vascular rejec-
tion [9].
Of the 4 heterozygous Phe152Ile patients, one had
ESRD at the time of diagnosis (patient 23, Table 3). All
other 3 patients were pyridoxine responsive; 2 of them
preserved their renal function over time with a follow-up
period of 9 and 25 years, respectively (patients 21 and 24,
Table 3). The only pyridoxine-responsive patient with a
decrease in renal function over time under treatment was
compound heterozygous for the Phe152Ile allele and the
Gly170Arg+Val336Asp allele (patient 22, Table 3).
The 33insC mutation. All 3 patients who were ho-
mozygous for the 33insC mutation developed ESRD
within their first year of life. Diagnosis was made at the
same time. Two of these patients died within one year
after the diagnosis was established (patients 25 to 27,
Table 3).
The Gly82Arg mutation. Pyridoxine responsiveness
was measured in 2 of 3 homozygous Gly82Arg patients
(patients 31 and 32, Table 3) and found negative in both.
One of these 2 patients had ESRD at the time of diagnosis
and received a combined liver and renal graft (patient
31, Table 3). The other patient showed a decline in renal
function over time. In the only patient that preserved
renal function over time, pyridoxine responsiveness was
not measured (patient 30, Table 3).
Single and double (compound) heterozygous muta-
tions. We found compound heterozygous mutations in
7 patients, 3 of whom had ESRD at the time of diagno-
sis (patients 16, 28, and 33, Table 3). The course of renal
function over time showed a great variation. Two out of
4 patients who were only heterozygous for one mutation
also had ESRD at the time of diagnosis (patients 12 and
23, Table 3).
DISCUSSION
We collected data on both the clinical characteris-
tics and genotypes in a large cohort of PH1 patients in
The Netherlands. The majority of the detected mutations
have previously been found in association with PH1. This
makes the AGXT mutation screening a useful tool in the
diagnostic work-up of PH1 patients in The Netherlands.
The Gly170Arg mutation
In our cohort of Dutch PH1 patients, the Gly170Arg
mutation was the most common mutation. Our finding
that this mutation was associated with pyridoxine respon-
siveness is consistent with other reports [10, 11]. Pre-
viously, Motley et al [12] have described the molecular
basis for the combination of severe hyperoxaluria and hy-
perglycoluria with the presence of a considerable AGT
activity in vitro and pyridoxine responsiveness in these
patients. They showed that the Gly170Arg mutation,
which is always located on the minor allele, results in
increased mistargeting of AGT to the mitochondria in-
stead of peroxisomes, which leads to inactivation of the
enzyme in vivo. This mitochondrial mistargeting of AGT
already occurs to a small extent (±5%) with AGT en-
coded by the minor allele because of the presence of a
Pro11Leu mutation [13]. This mutation creates a weak
mitochondrial targeting sequence in the amino terminus
of the encoded AGT. The Gly170Arg mutation increases
the efficiency of the mitochondrial targeting sequence by
delaying the dimerization of AGT and consequently by
preventing the folding of the protein [2, 14]. As a result of
this, the amino terminus remains accessible for mitochon-
drial import. Pyridoxine increases the residual activity of
the 10% peroxisomal-located AGT. Previously, there has
been discussion whether this relatively favorable biologi-
cal background (i.e., the pyridoxine responsiveness) is in
line with the clinical outcome of patients with this mu-
tation. All homozygous Gly170Arg cohort patients who
had a preserved renal function at the time of diagno-
sis and who were treated accordingly with pyridoxine,
a high fluid intake, and potassium citrate were able to
preserve renal function throughout the follow-up period.
However, 5 homozygous patients had already developed
ESRD at the time of diagnosis. Therefore, renal function
can be preserved in patients with a Gly170Arg mutation
(but without a Val336Asp mutation, as discussed below)
after a timely diagnosis and treatment with pyridoxine.
This is supported by the course of isolated renal trans-
plantations in Gly170Arg-positive patients in our cohort.
In contrast to what might be expected in PH1 patients
with isolated kidney transplantation, renal function was
preserved in 4 out of 6 of these patients after a median
follow-up of more than 7 years, most likely as a conse-
quence of pyridoxine therapy.
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The Val336Asp mutation
A novel mutation, 1007T>A (1129T>A), was found
in 2 patients and their relatives, which results in the
amino acid replacement Val336Asp. The mutation was
present on the minor allele and in combination with the
frequent Gly170Arg mutation. While Gly170Arg is cor-
related with pyridoxine responsiveness, the Val336Asp
mutation appears to interfere in a negative way with the
effect of pyridoxine, and in fact, predisposes to the de-
velopment of renal insufficiency, at least in homozygous
patients.
The Phe152Ile mutation
We found a relatively high number of patients carry-
ing the Phe152Ile mutation. This mutation has previously
been described in 6 patients [1, 10, 15]. However, this is
the first time that homozygous patients for this mutation
are reported. The high prevalence of Phe152Ile in our
study, when compared to others, suggests a founder ef-
fect. The beneficial effect of pyridoxine in these patients
is in line with observations previously made [1].
The 33insC mutation
The 33insC mutation is the third most common mu-
tation found in our study. Patients affected by this mu-
tation in a homozygous condition all suffered from the
most severe form of infantile PH1, with ESRD before
the first birthday. In the 2 patients who were compound
heterozygous for the 33insC mutation, the onset of symp-
toms and development of ESRD was much later, and the
level of AGT activity was higher than in the homozygous
patients. In previous studies, the 33insC mutation has also
been found [10, 16]. The results of the study by Milose-
vic et al are in line with our findings [16]. Remarkably, a
study by Amoroso et al revealed the opposite effect of
the homozygous and heterozygous 33insC mutation: the
worst outcome was shown by the heterozygous patient
(no pyridoxine responsiveness, no residual AGT activ-
ity), in contrast to a milder phenotype in 2 homozygous
patients who both appeared to be pyridoxine responsive,
and only 1 of whom developed ESRD [10]. This seems
hard to explain because the insertion of a nucleotide at
residue 33 (156) will result in a reading frame shift and in-
troduces a termination codon at residue 44 (167). The re-
sulting truncated protein would not be predicted to have
any enzyme activity, if synthesized at all. The fact that a
heterozygous patient for this mutation was responsive to
pyridoxine therapy can be explained by the presence of
the Gly170Arg mutation.
The Gly82Arg mutation
Although all 3 Gly82Arg homozygous patients had a
normal renal function at the time of diagnosis, 2 of them
suffered from progressive renal insufficiency over time.
Both patients were not responsive to pyridoxine. As far
as we know, these 2 families are the first ever described
with this mutation. This mutation parallels the previously
reported Gly82Glu mutation with respect to the pyridox-
ine unresponsiveness [2]. Zhang et al showed that binding
of pyridoxine to AGT has become impossible under in-
fluence of the Gly82Glu mutation as a result of a change
in the crystal structure of AGT [17]. It seems likely that
the same occurs in the Gly82Arg mutation.
Heterozygous and compound heterozygous mutations
In 4 patients, only 1 heterozygous mutation could
be found. Purdue et al and Milosevic et al already
showed that in patients who were heterozygous for the
Gly170Arg allele and homozygous for the minor allele,
only the mutant allele was expressed, indicating that the
other allele contained a mutation affecting its transcrip-
tion or protein stability [12, 16]. However, of the 3 pa-
tients heterozygous for the Gly170Arg allele, only 1 was
homozygous for the minor allele, suggesting that there
may be more alleles that are not expressed. No liver sam-
ples were available to test at the transcription level.
Like the true heterozygous patients, all compound het-
erozygous patients showed a great variation in clinical
outcome.
Clinical implications. This study shows a clear associa-
tion between homozygosity for Gly170Arg and Phe152Ile
mutation on one side, and pyridoxine responsiveness
on the other side. The clinical course of these patients
suggests that early treatment preserves renal function.
Therefore, we believe that the combination of these par-
ticular mutations, hyperoxaluria, hyperglycoluria, and
pyridoxine responsiveness abolishes the need for AGT
assessment because this will not reveal anything that
might influence the treatment policy. The same counts
for homozygous 33insC patients with neonatal onset of
disease who do not respond to pyridoxine. In all other
cases, AGT assessment remains a necessary tool in the
diagnostic work up of PH1.
Mutation analysis might also play a role in the preven-
tion of disease in the relatives of PH1 patients. Family
members who are also affected but not yet diagnosed
may benefit from an early conservative treatment with
pyridoxine. Our study showed that affected siblings who
were found by screening had a better outcome compared
with the proband, despite the fact that they inherited the
same mutation.
Finally, mutation analysis in ESRD PH1 patients might
be useful in the decision whether to perform combined
liver-kidney or isolated kidney transplantation. There-
fore, we believe that even in those PH1 patients who
already have developed an ESRD, AGXT mutation anal-
ysis can be very useful. It seems defensible only to
perform isolated kidney transplantation in homozygous
Gly170Arg or Phe152Ile patients. On the other hand, the
adverse outcome of the pyridoxine negative 33insC and
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Gly82Arg mutations give more argument for a combined
liver-kidney, or a timely planned liver transplantation in
these patients.
We therefore believe that mutation analysis should be
an integral part of the diagnostic work-up of patients.
Limitations of the study
We tried to make a complete overview of PH1 muta-
tions in a recently set up cohort of PH1 patients, com-
prising the entire spectrum of the disease. Some patients,
however, have been lost to follow-up (death, refusal to
participate), resulting in a smaller cohort than clinically
described before. Other factors like diet and levels of cit-
rate, pH in the urine, may also interplay in the process of
renal tissue damage. As clinical data were obtained ret-
rospectively, these factors have not been assessed in our
study.
CONCLUSION
Mutation analysis in patients with PH1 has shown to
be an important diagnostic tool in PH1 and should be
applied in all patients with severe hyperoxaluria. Assess-
ment of a well-known mutation in a patient with severe
hyperoxaluria might abolish the need for the invasive
liver biopsy in establishing the diagnosis PH1. Moreover,
our data have shown that in certain PH1 patients, muta-
tion analysis can also be used as a guide in the therapeutic
approach of these patients.
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